Chapter 19 of 25
- Confirm pathology, extent and prior treatment
- Integrate molecular group and recurrence risk
- Discuss intent, benefits, harms and patient priorities
- Agree a multidisciplinary plan and reassessment
What you will learn
- Understand the purpose of recurrence-risk groups.
- Compare observation, brachytherapy, pelvic radiation and systemic treatment.
- Recognize where molecular classification changes older recommendations.
Risk assessment after surgery
The final assessment combines FIGO stage, histology, grade, LVSI, nodes and molecular group. The 2025 ESGO–ESTRO–ESP framework also refines NSMP using grade and ER. A stage number alone is not enough to assign low, intermediate, high-intermediate or high risk. Ask the team to identify the actual features placing you in a group.
If molecular results are pending and could change treatment, discuss whether waiting for them is appropriate. A pathogenic POLE result can support treatment reduction in eligible early disease, whereas p53-abnormal invasive cancer can strengthen the rationale for more intensive treatment. Advanced disease and uncertain POLE variants must not be treated as favourable early-stage POLE cancer.
Typical options, not a self-prescribing table
| Risk context | Common discussion |
|---|---|
| Low risk | Observation after adequate surgery |
| Intermediate risk | Vaginal brachytherapy to reduce vaginal recurrence; observation in selected cases |
| High-intermediate risk | Pelvic external-beam radiation, with selected alternatives depending on staging and other features |
| High risk | Chemotherapy and radiation combinations or other guideline-supported systemic/local strategies |
Observation means a follow-up plan and symptom education. It avoids treatment toxicity when the expected absolute benefit is small. Vaginal brachytherapy targets the cuff; pelvic radiation treats a wider area. Chemotherapy addresses systemic recurrence risk but adds different toxicities. The choice should explain both the site of recurrence being prevented and the size of expected benefit.
Evidence behind the choices
PORTEC-1 demonstrated local-control benefit from pelvic radiation without a clear survival advantage in its selected early-stage population. PORTEC-2 showed that vaginal brachytherapy was an appropriate less burdensome option for selected high-intermediate-risk patients, while pelvic control differed. Neither trial should be converted into a blanket rule for every modern molecular subgroup.
PORTEC-3's 2025 ten-year report found improved overall and recurrence-free survival with chemoradiotherapy versus radiation alone in high-risk patients. Its molecular analysis was post-hoc and available for a subset; the strongest suggested benefit was in p53-abnormal disease. It does not prove that every patient in another molecular group gains no benefit.
Uncertainty and special situations
Aggressive histology without myometrial invasion and some uncommon molecular combinations have less certain evidence. A specialist tumour board should discuss observation versus additional treatment in context rather than apply a simplistic “high grade equals chemotherapy” rule. If nodes were not assessed, the implications depend on disease risk and why assessment was omitted.
Routine immunotherapy after surgery for every early-stage MMRd cancer is not established. Selected higher-stage or high-risk contexts may have guideline-supported options, but eligibility, trial evidence and regional labels must be checked. RAINBO is testing molecularly tailored postoperative strategies; those research questions should not be presented as completed results.
Questions and take-home messages
Ask: What is my recurrence-risk group? Where is recurrence most likely without treatment? What absolute benefit is expected? What lasting effects might treatment cause? Is observation reasonable? A second opinion can help when the benefit is uncertain or recommendations differ. The best plan is not necessarily the most intensive one, but it should clearly explain why its balance fits your disease and priorities.
Related chapters
- Treatment of Advanced and Metastatic Disease
- Molecular Classification: The Four Major Groups
- How Doctors Choose Treatment
References and review status
- ESGO–ESTRO–ESP endometrial carcinoma guideline update, 2025
- PORTEC-1: fifteen-year outcomes, 2011
- PORTEC-2: ten-year outcomes, 2018
- PORTEC-3: ten-year outcomes and molecular analysis, 2025
- RAINBO molecularly directed research programme protocol, 2023
Evidence/editorial check: 30 October 2026. Individual physician review is not recorded. Local approvals, resources and clinical guidance must be confirmed by the treating team.
Evidence scope and update policy